Core Viewpoint - A high dividend yield, such as TriplePoint Venture Growth's (NYSE: TPVG) current yield of 17.9%, often indicates potential concerns regarding the company's financial health [1] Group 1 - TriplePoint Venture Growth has a current dividend yield of 17.9% [1]

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation ...

Hims & Hers (HIMS 6.81%) is attracting investors looking to buy the dip in this impressive growth stock.*Stock prices used were the afternoon prices of June 24, 2025. The video was published on June 26, 2025. ...

Michael Saylor, the tech entrepreneur who founded the enterprise software provider Strategy (formerly known as MicroStrategy), has a net worth estimated at $9.3 billion. In the past few years, his focus has shifted to Bitcoin, the world's most valuable cryptocurrency. Saylor's business is now accumulating huge amounts of the digital asset.Based on his view that Bitcoin could skyrocket to $13 million per unit by 2045, Saylor is also implying that this popular exchange-traded fund (ETF), sponsored by giant as ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Despite similar valuations, one looks more attractive for long-term investors.While Nvidia gets all the attention among companies providing chips and equipment to AI data centers, there are dozens of others benefiting from the soaring spending from the industry's hyperscalers. Advanced Micro Devices (AMD 0.05%) and Arista Networks (ANET -2.17%) have both seen their revenue climb thanks to ongoing AI spending. But if you can buy only one of them, AMD is the stock to own right now.Both companies are executing ...

The media giant shares are up 35% since the start of last year. It's putting the magic back in the kingdom.Some upticks sneak up on you. Shares of Walt Disney (DIS 0.77%) notched a fresh 52-week high on Thursday and again on Friday this week. This follows the media giant scoring a 23% jump last year, matching the S&P 500's return after falling short in each of the three previous years. The media giant is actually winning so far in 2025.Disney stock's 11% ascent this year heading into the weekend may not see ...

Group 1 - The article introduces a series focused on REITs for retirees, highlighting the first two out of ten recommended REITs [1] - The company offers a comprehensive research platform called iREIT®, which includes data on various investment vehicles such as REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers [1] - The iREIT® Tracker provides insights on over 250 tickers, including quality scores, buy targets, and trim targets [1] Group 2 - A new Ratings Tracker named iREIT Buy Zone has been added to assist members in screening for value [2] - The company is promoting a free 2-week trial for members to explore the new features [2] - The offer includes a free book along with the trial [4]

Core Insights - The weight management medicines market is experiencing significant growth, with Eli Lilly positioned to dominate through the end of the decade due to its strong pipeline and clinical successes [1][9] - Eli Lilly's primary competitor in this space is Novo Nordisk, with both companies having deep pipelines and successful products [2][4] Group 1: Competitive Landscape - Eli Lilly's tirzepatide has shown superior efficacy compared to Novo Nordisk's semaglutide in clinical trials [5] - Novo Nordisk's next-generation medicine, CagriSema, achieved a mean weight loss of 22.7% after 68 weeks, falling short of its 25% target, which may hinder its commercial success [6][5] - Eli Lilly has additional promising candidates, including orforglipron and retatrutide, which could further enhance its competitive edge [7] Group 2: Strategic Moves - Eli Lilly is partnering with Camurus to utilize FluidCrystal technology for long-acting delivery of injectable therapies, addressing the issue of weight regain after discontinuation of medications [8] Group 3: Financial Performance - Eli Lilly reported a 45% year-over-year revenue increase to $12.7 billion and a 29% increase in net income to $3 billion in the first quarter [11] - Despite a higher forward price-to-earnings (P/E) ratio of 35.3 compared to the healthcare industry's average of 15.9, Eli Lilly's growth justifies the premium [11] Group 4: Investment Outlook - Eli Lilly is not solely focused on diabetes or weight loss, as it has also developed breakthrough medicines in other therapeutic areas, including Alzheimer's disease [10] - The company's strong financial results and promising pipeline make its stock an attractive long-term investment [12]

Group 1 - Tesla's stock is facing challenges with analysts predicting a nearly 30% drop in earnings for the next quarter compared to the same period last year, while its price-to-sales ratio remains high at 12.6 [1] - Rivian Automotive, another player in the electric vehicle market, has a significantly lower price-to-sales ratio of 2.9, indicating a stark contrast in valuation between the two companies [1] - Tesla's current sales heavily rely on two models, the Model 3 and Model Y, which have starting prices below $50,000, aligning with consumer preferences in the U.S. [3] Group 2 - Federal tax credits of up to $7,500 have historically made Tesla vehicles more affordable, boosting demand for the Model 3, Model Y, and even the Cybertruck [4] - A proposed bill by President Donald Trump aims to eliminate federal EV tax incentives, which could significantly impact Tesla's sales, as over half of EV buyers consider these credits crucial for their purchase decisions [6] - The experience in Germany, where the abrupt end of EV incentives led to a 16% drop in EV sales over six months, serves as a warning for potential outcomes in the U.S. market if tax credits are removed [6]